Haemonetics Corporation (HAE)

Gross profit margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Gross profit (ttm)	US$ in thousands	691,548	671,891	652,731	640,099	615,097	595,159	575,017	539,680	505,502	450,998	432,690	415,893	397,838	429,588	437,381	458,637	484,513	482,166	465,291	450,198
Revenue (ttm)	US$ in thousands	2,596,175	2,424,725	2,393,776	2,373,078	2,323,237	1,114,154	1,068,622	1,011,034	987,485	954,649	935,251	904,840	862,112	882,733	901,332	944,412	989,857	1,000,660	989,046	978,061
Gross profit margin		26.64%	27.71%	27.27%	26.97%	26.48%	53.42%	53.81%	53.38%	51.19%	47.24%	46.26%	45.96%	46.15%	48.67%	48.53%	48.56%	48.95%	48.18%	47.04%	46.03%

March 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $691,548K ÷ $2,596,175K
= 26.64%

The gross profit margin of Haemonetics Corporation has exhibited some fluctuations over the past few quarters. The margin declined from 53.81% in December 2022 to 26.64% in March 2024. Generally, the margin has been hovering around the mid-20% to mid-50% range. The company experienced a significant drop in gross profit margin in recent quarters, indicating a potential decrease in profitability related to cost of goods sold or pricing strategies. Further analysis into the factors affecting the gross profit margin is necessary to assess the company's overall performance and financial health.